

DRUGS FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS: GLOBAL MARKETS



PHM159A
March 2014

Sanjukta Bhattacharyya
Project Analyst

ISBN: 1-56965-754-8

bcc | Research
Market Forecasting

BCC Research
49 Walnut Park, Building 2
Wellesley, MA 02481 USA
866-285-7215 (toll-free within the USA),
or (+1) 781-489-7301
www.bccresearch.com
information@bccresearch.com

TABLE OF CONTENTS

TOPIC	PAGE NO.
CHAPTER 1 INTRODUCTION	2
STUDY GOALS AND OBJECTIVES	2
REASONS FOR DOING THIS STUDY	2
SCOPE OF REPORT	2
INTENDED AUDIENCE	2
METHODOLOGY	2
INFORMATION SOURCES	2
ANALYST'S CREDENTIALS	3
RELATED BCC RESEARCH REPORTS	3
BCC RESEARCH ONLINE SERVICES	3
DISCLAIMER	3
CHAPTER 2 EXECUTIVE SUMMARY	5
<i>SUMMARY TABLE A GLOBAL SALES OF DRUGS TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, BY REGION, THROUGH 2018 (MILLIONS)</i>	5
<i>SUMMARY FIGURE A GLOBAL SALES OF DRUGS TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, BY REGION, 2012-2018 (%)</i>	5
<i>SUMMARY TABLE B GLOBAL SALES OF DRUG CLASSES USED TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, THROUGH 2018 (\$ MILLIONS)</i>	7
<i>SUMMARY FIGURE B GLOBAL SLE MARKET-SHARE OF DRUG CLASSES USED TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, 2012-2018 (%)</i>	8
KEY FACTORS DRIVING THE MARKET	8
KEY FACTORS RESTRICTING THE MARKET	9
<i>NOTABLE PIPELINE ACTIVITIES</i>	9
KEY CHALLENGES IN THE MARKET FOR SLE THERAPIES	10
KEY OPPORTUNITIES IN THE MARKET FOR SLE THERAPIES	10
<i>SUMMARY TABLE C SUMMARY OF KEY PARAMETERS OF SYSTEMIC LUPUS ERYTHEMATOSUS MARKET, THROUGH 2018</i>	11
CHAPTER 3 OVERVIEW	14
SIGNS AND SYMPTOMS	14
TYPES OF LUPUS	16
SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)	16
CUTANEOUS LUPUS ERYTHEMATOSUS (CLE)	16
DRUG-INDUCED LUPUS	16
NEONATAL LUPUS ERYTHEMATOSUS	16
PATHOPHYSIOLOGY	17
DISEASE DEFINITION	17
CLINICAL MANIFESTATIONS	17
<i>TABLE 1 PERCENTAGE OF PATIENTS WITH DIFFERENT CLINICAL MANIFESTATIONS OF SLE DISEASE</i>	17
<i>TABLE 2 DESCRIPTION OF DIFFERENT TYPES OF SLE DISEASE MANIFESTATIONS</i>	18
<i>TABLE 3 CLASSIFICATION OF LUPUS NEPHRITIS</i>	20
<i>TABLE 4 WORLD HEALTH ORGANIZATION CLASSIFICATION OF LUPUS NEPHRITIS</i>	20
PROGRESSION AND SEVERITY	22
ETIOLOGY	23
GENETIC FACTORS	23

TOPIC	PAGE NO.
ENVIRONMENTAL FACTORS	25
Ultraviolet Light:	25
HORMONAL FACTORS	25
EPIDEMIOLOGY AND PATIENT POPULATIONS	25
U.S.	26
FRANCE	26
GERMANY	27
U.K.	27
SPAIN	27
ITALY	27
JAPAN	27
DIAGNOSED AND DRUG TREATED POPULATION	28
<i>TABLE 5 DIAGNOSED PREVALENCE AND DRUG TREATED SLE PATIENT POPULATION</i>	29
CHAPTER 4 CURRENT MEDICAL PRACTICE AND MARKET PROFILES	31
DIAGNOSIS SCREENING AND PUBLIC AWARENESS	31
KEY DIAGNOSTIC TESTS	31
Serologic Tests	31
Anti-nuclear Antibody (ANA)	31
Antibodies to Extractable Nuclear Antigens (ENAs)	32
Prognostic Markers and the Role of Autoantibodies	32
CLINICAL RECOMMENDATIONS AND DIAGNOSIS ALGORITHM	32
<i>FIGURE 1 DIAGNOSIS OF SYSTEMIC LUPUS ERYTHEMATOSUS</i>	32
DIFFERENTIAL DIAGNOSIS	33
<i>TABLE 6 DIAGNOSIS OF SYSTEMIC LUPUS ERYTHEMATOSUS BASED ON MANIFESTATIONS</i>	34
<i>FIGURE 2 PATIENT CARE PATH IN SYSTEMIC LUPUS ERYTHEMATOSUS</i>	35
<i>FIGURE 3 TREATMENT DECISION TREE FOR SYSTEMIC LUPUS ERYTHEMATOSUS</i>	36
<i>TABLE 7 TREATMENT ALGORITHM OF SYSTEMIC LUPUS ERYTHEMATOSUS</i>	37
REFERRAL PATTERNS	39
U.S.	39
FRANCE	40
GERMANY	42
U.K.	43
SPAIN	44
ITALY	44
JAPAN	45
CHAPTER 5 CURRENT THERAPIES	48
<i>TABLE 8 CURRENT DRUGS USED IN THE TREATMENT FOR SYSTEMIC LUPUS ERYTHEMATOSUS AND THEIR MECHANISM</i>	48
ANTIMALARIAL DRUGS	50
NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS)	50
CORTICOSTEROIDS	50
CYTOTOXIC AND IMMUNOSUPPRESSIVE DRUGS	51
CYCLOPHOSPHAMIDE	51
Azathioprine	51
MYCOPHENOLATE MOFETIL	51

TOPIC	PAGE NO.
METHOTREXATE	52
CYCLOSPORINE	52
TACROLIMUS	52
BIOLOGICS	52
B-CELL TARGETED THERAPY	53
BLYS-BLOCKERS (BELIMUMAB)	53
BIOLOGICS APPROVED FOR TREATING SLE	53
BELIMUMAB	53
<i>TABLE 9 BELIMUMAB EFFICACY DATA (BLISS-52: PRIMARY ENDPOINT AND COMPONENTS OF SLE RESPONDER INDEX)</i>	55
<i>TABLE 10 ENDPOINTS USED IN CLINICAL TRIALS FOR SLE</i>	56
BIOLOGICS USED OFF-LABEL	56
ANTI-CD20 ANTIBODY: RITUXIMAB (RITUXAN/MABTHERA; BIOGEN IDEC/ROCHE/ZENYAKU KOGYO)	56
SMALL MOLECULES	58
<i>TABLE 11 CURRENT THERAPIES FOR SYSTEMIC LUPUS ERYTHEMATOSUS, TREATMENT BY DAILY DOSE AND THE MANIFESTATION TARGETED</i>	59
<i>TABLE 12 TREATMENT FOR SYSTEMIC LUPUS ERYTHEMATOSUS BASED ON ORGAN INVOLVEMENT AND DISEASE SEVERITY</i>	60
<i>TABLE 13 STEROIDS USED FOR TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS ACROSS DIFFERENT DISEASE SEVERITY</i>	60
CHAPTER 6 UNMET NEEDS	62
EFFICACY AND SAFETY	63
NEED FOR PREVENTION OF ATHEROSCLEROSIS	63
STEROID SPARING THERAPY TO REDUCE THE DOSE AND DURATION OF STEROID USE	64
THERAPIES TAILORED TO INDIVIDUAL PATIENTS	64
PREVENTION OF NEUROCOGNITIVE DYSFUNCTION	65
PREVENTION OF OSTEOPOROSIS AND OSTEONECROSIS	66
EARLY DIAGNOSIS	66
CHAPTER 7 EMERGING THERAPIES	68
DRUG DEVELOPMENT AND REGULATORY CHALLENGES	68
EMERGING THERAPIES	69
B-CELL MODULATORS	69
BELIMUMAB	69
ATACICEPT	70
EPRATUZUMAB	70
TABALUMAB:	71
RIGERIMOD	71
BLISIBIMOD	72
T-CELL MODULATORS	72
IMMUNOSUPPRESSIVE AND CYTOTOXIC DRUGS	73
PROINFLAMMATORY AND CYTOKINE INHIBITORS	73
ANTI-IFN-A/ γ	73
<i>TABLE 14 EMERGING THERAPIES BY PHASES OF DEVELOPMENT</i>	73
<i>TABLE 15 NUMBER OF PROGRAMS AT EACH CLINICAL PHASES OF CLINICAL DEVELOPMENT</i>	76

TOPIC	PAGE NO.
<i>FIGURE 4 NUMBER OF PROGRAMS AT EACH CLINICAL PHASE</i>	76
<i>TABLE 16 POSITIONING OF LEADING EMERGING THERAPIES FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS IN THE FUTURE</i>	77
CHAPTER 8 MARKET OUTLOOK	79
<i>TABLE 17 GLOBAL SALES OF DRUGS TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, 2012-2018 (\$ MILLIONS)</i>	80
<i>TABLE 18 GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET -SALES IN MAJOR MARKETS, THROUGH 2018 (\$ MILLIONS)</i>	80
<i>TABLE 19 GLOBAL SALES OF DRUG CLASSES USED TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, THROUGH 2018 (\$ MILLIONS)</i>	80
<i>FIGURE 5 GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET-VALUE OF DRUG CLASSES, 2013 AND 2018</i>	81
UNITED STATES	82
<i>TABLE 20 U.S. — SALES OF DRUG CLASSES USED TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, 2012-2018 (\$ MILLIONS)</i>	82
<i>FIGURE 6 U.S. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET-VALUE OF DRUG CLASSES, 2013 AND 2018 (\$ MILLIONS)</i>	82
FRANCE	83
<i>TABLE 21 FRANCE: SALES OF DRUG CLASSES USED TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, THROUGH 2018 (\$ MILLIONS)</i>	83
<i>FIGURE 7 FRANCE: SYSTEMIC LUPUS ERYTHEMATOSUS MARKET-VALUE OF DRUG CLASSES, 2013 AND 2018 (\$ MILLIONS)</i>	83
GERMANY	84
<i>TABLE 22 GERMANY: SALES OF DRUG CLASSES USED TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, THROUGH 2018 (\$ MILLIONS)</i>	84
<i>FIGURE 8 GERMANY: SYSTEMIC LUPUS ERYTHEMATOSUS MARKET-VALUE OF DRUG CLASSES, 2013 AND 2018 (\$ MILLIONS)</i>	84
U.K.	85
<i>TABLE 23 U.K.: SALES OF DRUG CLASSES USED TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, THROUGH 2018 (\$ MILLIONS)</i>	85
<i>FIGURE 9 U.K: SYSTEMIC LUPUS ERYTHEMATOSUS MARKET-VALUE OF DRUG CLASSES, 2013 AND 2018 (\$ MILLIONS)</i>	85
SPAIN	86
<i>TABLE 24 SPAIN: SALES OF DRUG CLASSES USED TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, THROUGH 2018 (\$ MILLIONS)</i>	86
<i>FIGURE 10 SPAIN: SYSTEMIC LUPUS ERYTHEMATOSUS MARKET-VALUE OF DRUG CLASSES, 2013 AND 2018 (\$ MILLIONS)</i>	86
ITALY	87
<i>TABLE 25 ITALY: SALES OF DRUG CLASSES USED TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, THROUGH 2018 (\$ MILLIONS)</i>	87
<i>FIGURE 11 ITALY: SYSTEMIC LUPUS ERYTHEMATOSUS MARKET-VALUE OF DRUG CLASSES, 2013 AND 2018 (\$ MILLIONS)</i>	87
JAPAN	88
<i>TABLE 26 JAPAN: SALES OF DRUG CLASSES USED TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, THROUGH 2018 (\$ MILLIONS)</i>	88
<i>FIGURE 12 JAPAN: SYSTEMIC LUPUS ERYTHEMATOSUS MARKET 2013-2018-VALUE OF DRUG CLASSES, 2013 AND 2018 (\$ MILLIONS)</i>	88
<i>TABLE 27 SALES OF BIOLOGICS AND SMALL MOLECULE DRUGS TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, THROUGH 2018 (\$ MILLIONS)</i>	89

TOPIC	PAGE NO.
<i>TABLE 28 SALES OF DRUGS TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS IN THE MAJOR PHARMACEUTICAL MARKET OF THE U.S., THROUGH 2018 (\$ MILLIONS)</i>	90
<i>TABLE 29 SALES OF DRUGS TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS IN THE MAJOR PHARMACEUTICAL MARKET OF FRANCE, THROUGH 2018 (\$ MILLIONS)</i>	91
<i>TABLE 30 SALES OF DRUGS TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS IN THE MAJOR PHARMACEUTICAL MARKET OF GERMANY, THROUGH 2018 (\$ MILLIONS)</i>	92
<i>TABLE 31 SALES OF DRUGS TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS IN THE MAJOR PHARMACEUTICAL MARKET OF THE U.K., THROUGH 2018 (\$ MILLIONS)</i>	93
<i>TABLE 32 SALES OF DRUGS TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS IN THE MAJOR PHARMACEUTICAL MARKET OF SPAIN, THROUGH 2018 (\$ MILLIONS)</i>	94
<i>TABLE 33 SALES OF DRUGS TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS IN THE MAJOR PHARMACEUTICAL MARKET OF ITALY, THROUGH 2018 (\$ MILLIONS)</i>	95
<i>TABLE 34 SALES OF DRUGS TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS IN THE MAJOR PHARMACEUTICAL MARKET OF JAPAN, THROUGH 2018 (\$ MILLIONS)</i>	96
CHAPTER 9 PATENTS	98
<i>TABLE 35 NO. OF PATENTS</i>	98
<i>TABLE 36 ISSUED PATENTS</i>	100
<i>TABLE 37 PATENT APPLICATIONS</i>	107
CHAPTER 10 COMPANY PROFILES	116
ANTHERA PHARMACEUTICALS INC	116
BIOTEST AG	116
BIOTICA TECHNOLOGY LTD.	117
CEPHALON	117
CORNERSTONE THERAPEUTICS INC.	118
CREABILIS THERAPEUTICS S.R.L.	118
DYNAVAX TECHNOLOGIES	119
ELI LILLY	119
F. HOFFMANN-LA ROCHE LTD	120
EVENTS OF 2013 AND 2014	120
GLAXOSMITHKLINE PLC (GSK)	121
HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT	122
HANSA MEDICAL AB	123
HARBOR BIOSCIENCES	123
IMMUNOMEDICS, INC.	124
IDERA PHARMACEUTICALS INC.	124
IMMUPHARMA PLC	125
JOHNSON & JOHNSON LTD.	126
ISOTECHNIKA PHARMA INC	127
KINETA INC.	128
KYORIN PHARMACEUTICALS CO. LTD	129
LYCERA CORPORATION	129
MERCK KGAA	129
MACROGENICS, INC.	131
NOVO NORDISK	132
NEOVACS S.A.	133
NASVAX LTD.	133
ONYX PHARMACEUTICALS INC.	133

TOPIC	PAGE NO.
PHARMACYCLIS	134
PORTOLA PHARMACEUTICALS INC.	135
PFIZER LIMITED	135
REVO BIOLOGICS	136
RIGEL PHARMACEUTICALS INC	137
SANOFI	137
TEVA PHARMACEUTICAL INDUSTRIES LTD.	138
UCB GROUP/ IMMUNOMEDICS	138
VACCINEX INC.	139

LIST OF TABLES

TABLE HEADING	PAGE NO.
SUMMARY TABLE A GLOBAL SALES OF DRUGS TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, BY REGION, THROUGH 2018 (MILLIONS)	5
SUMMARY TABLE B GLOBAL SALES OF DRUG CLASSES USED TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, THROUGH 2018 (\$ MILLIONS)	7
SUMMARY TABLE C SUMMARY OF KEY PARAMETERS OF SYSTEMIC LUPUS ERYTHEMATOSUS MARKET, THROUGH 2018	11
TABLE 1 PERCENTAGE OF PATIENTS WITH DIFFERENT CLINICAL MANIFESTATIONS OF SLE DISEASE	17
TABLE 2 DESCRIPTION OF DIFFERENT TYPES OF SLE DISEASE MANIFESTATIONS	18
TABLE 3 CLASSIFICATION OF LUPUS NEPHRITIS	20
TABLE 4 WORLD HEALTH ORGANIZATION CLASSIFICATION OF LUPUS NEPHRITIS	20
TABLE 5 DIAGNOSED PREVALENCE AND DRUG TREATED SLE PATIENT POPULATION	29
TABLE 6 DIAGNOSIS OF SYSTEMIC LUPUS ERYTHEMATOSUS BASED ON MANIFESTATIONS	34
TABLE 7 TREATMENT ALGORITHM OF SYSTEMIC LUPUS ERYTHEMATOSUS	37
TABLE 8 CURRENT DRUGS USED IN THE TREATMENT FOR SYSTEMIC LUPUS ERYTHEMATOSUS AND THEIR MECHANISM	48
TABLE 9 BELIMUMAB EFFICACY DATA (BLISS-52: PRIMARY ENDPOINT AND COMPONENTS OF SLE RESPONDER INDEX)	55
TABLE 10 ENDPOINTS USED IN CLINICAL TRIALS FOR SLE	56
TABLE 11 CURRENT THERAPIES FOR SYSTEMIC LUPUS ERYTHEMATOSUS, TREATMENT BY DAILY DOSE AND THE MANIFESTATION TARGETED	59
TABLE 12 TREATMENT FOR SYSTEMIC LUPUS ERYTHEMATOSUS BASED ON ORGAN INVOLVEMENT AND DISEASE SEVERITY	60
TABLE 13 STEROIDS USED FOR TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS ACROSS DIFFERENT DISEASE SEVERITY	60
TABLE 14 EMERGING THERAPIES BY PHASES OF DEVELOPMENT	73
TABLE 15 NUMBER OF PROGRAMS AT EACH CLINICAL PHASES OF CLINICAL DEVELOPMENT	76
TABLE 16 POSITIONING OF LEADING EMERGING THERAPIES FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS IN THE FUTURE	77
TABLE 17 GLOBAL SALES OF DRUGS TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, 2012-2018 (\$ MILLIONS)	80
TABLE 18 GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET -SALES IN MAJOR MARKETS, THROUGH 2018 (\$ MILLIONS)	80
TABLE 19 GLOBAL SALES OF DRUG CLASSES USED TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, THROUGH 2018 (\$ MILLIONS)	80
TABLE 20 U.S. — SALES OF DRUG CLASSES USED TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, 2012-2018 (\$ MILLIONS)	82
TABLE 21 FRANCE: SALES OF DRUG CLASSES USED TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, THROUGH 2018 (\$ MILLIONS)	83
TABLE 22 GERMANY: SALES OF DRUG CLASSES USED TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, THROUGH 2018 (\$ MILLIONS)	84
TABLE 23 U.K.: SALES OF DRUG CLASSES USED TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, THROUGH 2018 (\$ MILLIONS)	85
TABLE 24 SPAIN: SALES OF DRUG CLASSES USED TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, THROUGH 2018 (\$ MILLIONS)	86
TABLE 25 ITALY: SALES OF DRUG CLASSES USED TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, THROUGH 2018 (\$ MILLIONS)	87
TABLE 26 JAPAN: SALES OF DRUG CLASSES USED TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, THROUGH 2018 (\$ MILLIONS)	88

TABLE HEADING	PAGE NO.
TABLE 27 SALES OF BIOLOGICS AND SMALL MOLECULE DRUGS TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, THROUGH 2018 (\$ MILLIONS)	89
TABLE 28 SALES OF DRUGS TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS IN THE MAJOR PHARMACEUTICAL MARKET OF THE U.S., THROUGH 2018 (\$ MILLIONS)	90
TABLE 29 SALES OF DRUGS TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS IN THE MAJOR PHARMACEUTICAL MARKET OF FRANCE, THROUGH 2018 (\$ MILLIONS)	91
TABLE 30 SALES OF DRUGS TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS IN THE MAJOR PHARMACEUTICAL MARKET OF GERMANY, THROUGH 2018 (\$ MILLIONS)	92
TABLE 31 SALES OF DRUGS TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS IN THE MAJOR PHARMACEUTICAL MARKET OF THE U.K., THROUGH 2018 (\$ MILLIONS)	93
TABLE 32 SALES OF DRUGS TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS IN THE MAJOR PHARMACEUTICAL MARKET OF SPAIN, THROUGH 2018 (\$ MILLIONS)	94
TABLE 33 SALES OF DRUGS TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS IN THE MAJOR PHARMACEUTICAL MARKET OF ITALY, THROUGH 2018 (\$ MILLIONS)	95
TABLE 34 SALES OF DRUGS TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS IN THE MAJOR PHARMACEUTICAL MARKET OF JAPAN, THROUGH 2018 (\$ MILLIONS)	96
TABLE 35 NO. OF PATENTS	98
TABLE 36 ISSUED PATENTS	100
TABLE 37 PATENT APPLICATIONS	107

LIST OF FIGURES

FIGURE TITLE	PAGE NO.
SUMMARY FIGURE A GLOBAL SALES OF DRUGS TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, BY REGION, 2012-2018 (%)	5
SUMMARY FIGURE B GLOBAL SLE MARKET-SHARE OF DRUG CLASSES USED TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, 2012-2018 (%)	8
FIGURE 1 DIAGNOSIS OF SYSTEMIC LUPUS ERYTHEMATOSUS	32
FIGURE 2 PATIENT CARE PATH IN SYSTEMIC LUPUS ERYTHEMATOSUS	35
FIGURE 3 TREATMENT DECISION TREE FOR SYSTEMIC LUPUS ERYTHEMATOSUS	36
FIGURE 4 NUMBER OF PROGRAMS AT EACH CLINICAL PHASE	76
FIGURE 5 GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET-VALUE OF DRUG CLASSES, 2013 AND 2018	81
FIGURE 6 U.S. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET-VALUE OF DRUG CLASSES, 2013 AND 2018 (\$ MILLIONS)	82
FIGURE 7 FRANCE: SYSTEMIC LUPUS ERYTHEMATOSUS MARKET-VALUE OF DRUG CLASSES, 2013 AND 2018 (\$ MILLIONS)	83
FIGURE 8 GERMANY: SYSTEMIC LUPUS ERYTHEMATOSUS MARKET-VALUE OF DRUG CLASSES, 2013 AND 2018 (\$ MILLIONS)	84
FIGURE 9 U.K: SYSTEMIC LUPUS ERYTHEMATOSUS MARKET-VALUE OF DRUG CLASSES, 2013 AND 2018 (\$ MILLIONS)	85
FIGURE 10 SPAIN: SYSTEMIC LUPUS ERYTHEMATOSUS MARKET-VALUE OF DRUG CLASSES, 2013 AND 2018 (\$ MILLIONS)	86
FIGURE 11 ITALY: SYSTEMIC LUPUS ERYTHEMATOSUS MARKET-VALUE OF DRUG CLASSES, 2013 AND 2018 (\$ MILLIONS)	87
FIGURE 12 JAPAN: SYSTEMIC LUPUS ERYTHEMATOSUS MARKET 2013-2018-VALUE OF DRUG CLASSES, 2013 AND 2018 (\$ MILLIONS)	88